[go: up one dir, main page]

ID28959A - 3-SUBSTITUTED-4-ARYLINCINOLIN-2-ON FLOWS AS A POTASSIUM CHANNEL MODULATOR - Google Patents

3-SUBSTITUTED-4-ARYLINCINOLIN-2-ON FLOWS AS A POTASSIUM CHANNEL MODULATOR

Info

Publication number
ID28959A
ID28959A IDW00200101184A ID20011184A ID28959A ID 28959 A ID28959 A ID 28959A ID W00200101184 A IDW00200101184 A ID W00200101184A ID 20011184 A ID20011184 A ID 20011184A ID 28959 A ID28959 A ID 28959A
Authority
ID
Indonesia
Prior art keywords
arylincinolin
substituted
flows
potassium channel
channel modulator
Prior art date
Application number
IDW00200101184A
Other languages
Indonesian (id)
Inventor
Piyasena Hewawasam
John E Starrett Jr
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ID28959A publication Critical patent/ID28959A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
IDW00200101184A 1998-12-04 1999-12-01 3-SUBSTITUTED-4-ARYLINCINOLIN-2-ON FLOWS AS A POTASSIUM CHANNEL MODULATOR ID28959A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11107998P 1998-12-04 1998-12-04

Publications (1)

Publication Number Publication Date
ID28959A true ID28959A (en) 2001-07-19

Family

ID=22336494

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101184A ID28959A (en) 1998-12-04 1999-12-01 3-SUBSTITUTED-4-ARYLINCINOLIN-2-ON FLOWS AS A POTASSIUM CHANNEL MODULATOR

Country Status (28)

Country Link
US (1) US6184231B1 (en)
EP (1) EP1133474B1 (en)
JP (1) JP2002531549A (en)
KR (1) KR100641254B1 (en)
CN (1) CN1129582C (en)
AR (1) AR021867A1 (en)
AT (1) ATE354569T1 (en)
AU (1) AU755202B2 (en)
BR (1) BR9915744A (en)
CO (1) CO5150159A1 (en)
CZ (1) CZ20011965A3 (en)
DE (1) DE69935245T2 (en)
DK (1) DK1133474T3 (en)
ES (1) ES2281975T3 (en)
HU (1) HUP0201613A3 (en)
ID (1) ID28959A (en)
IL (1) IL142457A (en)
MY (1) MY115935A (en)
NO (1) NO318897B1 (en)
NZ (1) NZ510987A (en)
PE (1) PE20001327A1 (en)
PL (1) PL196955B1 (en)
PT (1) PT1133474E (en)
RU (1) RU2240998C2 (en)
TR (1) TR200101339T2 (en)
TW (1) TW495504B (en)
WO (1) WO2000034244A1 (en)
ZA (1) ZA200104455B (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02001207A (en) * 1999-08-03 2002-07-30 Abbott Lab Potassium channel openers.
US6436944B1 (en) * 1999-09-30 2002-08-20 Pfizer Inc. Combination effective for the treatment of impotence
TW562799B (en) * 1999-12-01 2003-11-21 Bristol Myers Squibb Co Preparation of 3-substituted-4-arylquinolin-2-one derivatives
AU2002213204A1 (en) * 2000-10-13 2002-04-22 Bristol-Myers Squibb Company Selective maxi-K- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
CA2469048A1 (en) * 2001-12-14 2003-06-26 Daniel Dube Quinolinones as prostaglandin receptor ligands
AU2003225305A1 (en) 2002-05-08 2003-11-11 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
US7632858B2 (en) * 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US6939968B2 (en) * 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
EP1587783A4 (en) * 2003-01-24 2006-11-08 Bristol Myers Squibb Co Cycloalkyl containing anilide ligands for the thyroid receptor
EP1594854B1 (en) 2003-02-06 2010-09-01 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
SI1618092T1 (en) 2003-05-01 2010-11-30 Bristol Myers Squibb Co Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
WO2005007628A1 (en) 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
JP2006528193A (en) * 2003-07-22 2006-12-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Quinolinone derivatives as inhibitors of C-FMS kinase
EP1667683A4 (en) * 2003-09-23 2009-04-29 Merck & Co Inc Quinoline potassium channel inhibitors
CA2539760C (en) * 2003-09-23 2011-01-25 Merck & Co., Inc. Quinoline potassium channel inhibitors
EP1670460B1 (en) 2003-10-10 2014-11-26 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
US7132542B2 (en) 2003-10-14 2006-11-07 Bristol-Myers Squibb Company Compounds for the treatment of male erectile dysfunction
US7145013B2 (en) * 2003-10-14 2006-12-05 Bristol-Myers Squibb Company 3-thia-4-arylquinolin-2-one derivatives
US7151180B2 (en) * 2003-10-14 2006-12-19 Bristol-Myers Squibb Company Potassium channel modulators
US7179920B2 (en) * 2003-10-14 2007-02-20 Bristol-Myers Squibb Company 3-thia-4-arylquinolin-2-one derivatives
US7002015B2 (en) * 2003-10-14 2006-02-21 Bristol-Myers Squibb Company 3-Thia-4-arylquinolin-2-one derivatives as smooth muscle relaxants
US7049309B2 (en) * 2003-10-14 2006-05-23 Bristol-Myers Squibb Company 3-Thia-4-arylquinolin-2-one potassium channel modulators
JP2007518686A (en) * 2003-10-17 2007-07-12 田辺製薬株式会社 High conductance calcium-sensitive K channel opener
KR20060111520A (en) * 2003-11-07 2006-10-27 카이론 코포레이션 Inhibition of FFFF3 and Treatment of Multiple Myeloma
US7256208B2 (en) * 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) * 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7253167B2 (en) * 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US8143425B2 (en) * 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
EP1652521A1 (en) * 2004-10-20 2006-05-03 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical composition of sildenafil and a large conductance Ca(2+) activated K+ channels activator
EP1676573A1 (en) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor
WO2006076598A2 (en) * 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7361766B2 (en) 2005-01-12 2008-04-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076597A1 (en) * 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
ATE421518T1 (en) * 2005-02-10 2009-02-15 Bristol Myers Squibb Co DIHYDROQUINAZOLINONES AS 5HT MODULATORS
AU2006216629A1 (en) * 2005-02-24 2006-08-31 Janssen Pharmaceutica N.V. Novel quinoline derivatives as potassium ion channel openers
US7632837B2 (en) * 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
TW200726765A (en) * 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US20060287342A1 (en) * 2005-06-17 2006-12-21 Mikkilineni Amarendra B Triazolopyrimidine heterocycles as cannabinoid receptor modulators
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7317012B2 (en) * 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
EA200800430A1 (en) * 2005-07-28 2008-06-30 Бристол-Маерс Сквибб Компани SUBSTITUTED TETRAHYDRO-1H-PYRIDO [4.3, B] INDOLS AS AGONISTS AND ANTAGONISTS OF SEROTONIN RECEPTORS
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
EP1757290A1 (en) * 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR059898A1 (en) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
KR20080091949A (en) * 2007-04-10 2008-10-15 에스케이케미칼주식회사 Pharmaceutical composition for the prevention and treatment of ischemic diseases containing lactone-type pyridine compounds
KR101520086B1 (en) 2007-09-14 2015-05-14 얀센 파마슈티칼스 인코포레이티드 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1'H-[1,4']bipyridinyl-2'-ones
CA2697399C (en) 2007-09-14 2016-01-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
SG185995A1 (en) 2007-11-16 2012-12-28 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication
EP2103602A1 (en) 2008-03-17 2009-09-23 AEterna Zentaris GmbH Novel 1,2,4-triazole derivatives and process of manufacturing thereof
JP5277256B2 (en) 2008-04-09 2013-08-28 田辺三菱製薬株式会社 Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers
CN102143955B (en) 2008-09-02 2013-08-14 Omj制药公司 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
CA2744138C (en) 2008-11-28 2015-08-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
UA108070C2 (en) 2009-05-12 2015-03-25 Аддекс Фарма С.А. Derivative of 1,2,4-triazole [4,3-a] pyridine and their application as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2409006T3 (en) 2009-05-12 2013-06-24 Janssen Pharmaceuticals Inc. 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
DE102010028362A1 (en) * 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft manufacturing
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
JP5852665B2 (en) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor
WO2012062759A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
AU2011328194B2 (en) 2010-11-08 2015-04-16 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6, 7- dihydropyrazolu [5,1-a] pyrazine-4 (5 hands) -on compounds and their use as negative excretory regulators of Miglore 2 receptors.
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
LT3431106T (en) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators of metabotropic glutamatergic receptor subtype 2 and their use
EA202192128A1 (en) 2014-02-04 2022-02-28 Янссен Фармацевтика Нв COMBINATIONS CONTAINING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR 2 SUBTYPES AND THEIR USE
TWI698438B (en) * 2015-03-13 2020-07-11 德商４Ｓｃ製藥公司 Kv1.3 inhibitors and their medical application
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
US20180207138A1 (en) 2017-01-23 2018-07-26 Cadent Therapeutics, Inc. Methods for the treatment of tremors by positive modulation of sk channels
WO2019018562A1 (en) * 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUNDS AS AhR MODULATORS
CN117229206B (en) * 2023-09-18 2025-01-03 延安大学 A method for preparing polysubstituted 2-quinolinone compounds by base catalysis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200422A (en) 1990-09-24 1993-04-06 Neurosearch A/S Benzimidazole derivatives, their preparation and use
NZ239540A (en) 1990-09-24 1993-11-25 Neurosearch As 1-phenyl benzimidazole derivatives and medicaments
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5565472A (en) 1992-12-21 1996-10-15 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
TW504504B (en) 1996-11-26 2002-10-01 Bristol Myers Squibb Co 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
CA2301549A1 (en) 1997-08-28 1999-03-04 Piyasena Hewawasam 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators

Also Published As

Publication number Publication date
DE69935245T2 (en) 2007-10-31
NO20012739D0 (en) 2001-06-01
EP1133474A1 (en) 2001-09-19
BR9915744A (en) 2001-08-21
AR021867A1 (en) 2002-08-07
KR100641254B1 (en) 2006-11-02
DE69935245D1 (en) 2007-04-05
CN1129582C (en) 2003-12-03
AU1749100A (en) 2000-06-26
PE20001327A1 (en) 2001-02-01
DK1133474T3 (en) 2007-04-10
PL348039A1 (en) 2002-05-06
ZA200104455B (en) 2002-05-30
RU2240998C2 (en) 2004-11-27
CO5150159A1 (en) 2002-04-29
TW495504B (en) 2002-07-21
EP1133474A4 (en) 2005-02-16
EP1133474B1 (en) 2007-02-21
ATE354569T1 (en) 2007-03-15
WO2000034244A1 (en) 2000-06-15
CZ20011965A3 (en) 2001-09-12
HUP0201613A2 (en) 2002-09-28
KR20010087409A (en) 2001-09-15
IL142457A (en) 2006-10-31
PT1133474E (en) 2007-04-30
PL196955B1 (en) 2008-02-29
HUP0201613A3 (en) 2003-03-28
JP2002531549A (en) 2002-09-24
NZ510987A (en) 2004-02-27
NO318897B1 (en) 2005-05-18
TR200101339T2 (en) 2002-02-21
AU755202B2 (en) 2002-12-05
ES2281975T3 (en) 2007-10-01
US6184231B1 (en) 2001-02-06
MY115935A (en) 2003-09-30
CN1329599A (en) 2002-01-02
NO20012739L (en) 2001-06-01

Similar Documents

Publication Publication Date Title
ID28959A (en) 3-SUBSTITUTED-4-ARYLINCINOLIN-2-ON FLOWS AS A POTASSIUM CHANNEL MODULATOR
DE69927787D1 (en) CHANNEL DEFINITION ARCHITECTURE ERWEITERUNG
DE69911533D1 (en) reservoir
DE69912141D1 (en) CURABLE PERFLUORELASTOMER COMPOSITION
NO20024042L (en) Aryl-fused azapolycyclic compounds
DE69929656D1 (en) seal
ID26162A (en) BENZILBIFENIL BIOSIDA DESIGNS
DE69908035D1 (en) weatherstrip
DE69918698D1 (en) CURABLE PERFLUORELASTOMER COMPOSITION
DE59901531D1 (en) Caterpillar
DE19983106T1 (en) Leadership mechanism
SE0102793A0 (en) channel element
ID26421A (en) GREENHOUSE
DE59802081D1 (en) GUIDE CONSTRUCTION
DE69929274D1 (en) flow
FI103617B1 (en) channel Transistors
FI980937A0 (en) Greenhouse
DE69906234D1 (en) gumming
DE59911550D1 (en) Guide unit
DE69937911D1 (en) Curable composition
DE69838855D1 (en) SPROCKET
DE69811889D1 (en) channel inductor
DK1349850T3 (en) Sodium channel modulators derived from 2-piperidylimidazoles
FI980973A (en) Double-calculated desulphurisation
NO995984D0 (en) A seal